Islamabad, Mar 18, 2025: A groundbreaking artificial intelligence (AI) tool is revolutionizing liver cancer treatment by accurately predicting the risk of recurrence.
Developed by a team of Chinese researchers, this innovative system boasts an impressive 82.2% accuracy rate in forecasting whether the disease will return after surgery.
Liver cancer remains a major global health concern, ranking third in cancer-related deaths, with recurrence rates as high as 70%.
The research, led by Sun Cheng at the University of Science and Technology of China, introduced a scoring model called TIMES.
This advanced tool evaluates the likelihood of relapse by analyzing the spatial distribution of immune cells within the tumor microenvironment.
Unlike conventional methods that focus solely on cell count, TIMES considers the spatial organization of immune cells, offering a more precise prediction model.
Utilizing cutting-edge technologies such as spatial transcriptomics, proteomics, multispectral immunohistochemistry, and AI-powered spatial analysis, the team developed a novel assessment system. The model was trained using liver cancer tissue samples from 61 patients, ensuring its reliability.
Read More:
Starbucks to Pay $50M for Burn Injury
To make this technology accessible worldwide, the researchers have launched an online platform where users can upload pathological staining images for instant risk evaluation.
Sun Cheng highlighted the significance of this tool in enhancing personalized treatment plans, particularly in resource-limited medical settings.
The team is currently collaborating with industry leaders to integrate TIMES into standard clinical practice, ensuring wider adoption of this life-saving innovation.
This AI-driven breakthrough marks a significant step forward in liver cancer treatment, providing doctors with a powerful tool to improve patient outcomes and make informed decisions about post-surgical care.
